Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure.
about
"Nihilism" of chronic heart failure therapy in children and why effective therapy is withheldNeural control of the circulation: how sex and age differences interact in humansThe relationship between the MMP system, adrenoceptors and phosphoprotein phosphatasesKetotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteersCardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effectscAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonistsAssociation of the beta-1 adrenergic receptor carboxyl terminal variants with left ventricular hypertrophy among diabetic and non-diabetic survivors of acute myocardial infarction.Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading.β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosisComparison of non-invasive methods for the assessment of haemodynamic drug effects in healthy male and female volunteers: sex differences in cardiovascular responsiveness.Plasma concentrations and effects of salbutamol administered orally to patients with cystic fibrosisLack of effect of chronic calcium antagonist treatment on beta 1- and beta 2-adrenoceptors in right atria from patients with or without heart failureTotal beta-adrenoceptor knockout slows conduction and reduces inducible arrhythmias in the mouse heart.Cardiovascular changes after administration of aerosolized salbutamol in horses: five cases.Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases.Selective beta1-adrenoceptor blockade enhances the activity of the stimulatory G-protein in human atrial myocardium.Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy.Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography.Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.Reduced beta-adrenergic receptor activation decreases G-protein expression and beta-adrenergic receptor kinase activity in porcine heartEpigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy.Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy.Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.beta(1)- and beta(2)-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non-failing adult human heart.Time-dependent evolution of functional vs. remodeling signaling in induced pluripotent stem cell-derived cardiomyocytes and induced maturation with biomechanical stimulationCardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced myocardial necrosis: a new therapeutic implicationGene therapy in heart failure.Albuterol Improves Alveolar-Capillary Membrane Conductance in Healthy Humans.Functional beta3-adrenoceptor in the human heart.Effect of pretreatment with coenzyme Q10 on isoproterenol-induced cardiotoxicity and cardiac hypertrophy in rats.Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin ReceptorsRegulation of beta-adrenoceptor density and mRNA levels in the rat heart cell-line H9c2Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors.Raf kinase inhibitor protein: lessons of a better way for β-adrenergic receptor activation in the heart.The effect of SK&F 95654, a novel phosphodiesterase inhibitor, on cardiovascular, respiratory and platelet function.Adenosine A1 receptors heterodimerize with β1- and β2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling.Cardiovascular actions of dopexamine in anaesthetized and conscious dogs.
P2860
Q26768688-F8462A9F-55E8-4E8A-A9D2-3C56741F0CEFQ27001664-F80244FF-10A8-424F-8ADC-9448961E4867Q27003263-1AAB33A1-90C9-409A-8C12-925EF0E14B28Q28343197-EECB0BA0-EC54-407B-BB63-35AFA9B8132EQ28368969-88AF9DC7-4DD3-4DD1-9E70-2552C1C7480AQ28592167-01DC2114-86E6-4BFD-9DC7-AA1CEE32ACB0Q33617881-F42EC7E1-CABE-4E5D-918C-476BC9701118Q34105285-707981D9-1A86-4117-9CD0-C250A5EA712BQ34275561-EAD8DE96-A597-4546-A854-6065A6E2AD03Q34344600-EA6990D4-C1C2-4BDF-8D0F-F7DBFAF1AFFEQ34347466-DD934BF0-AC1C-450B-8D06-F7846065DA35Q34347531-8EBE4B9B-2B5E-4557-BBEF-A44BD3377392Q34402801-64AA06AF-8384-495D-B193-D4E71B0D698AQ34469952-E2931779-270B-47EF-9F80-62990634A106Q34538228-5ECE46D5-0FE8-44FB-8B33-3445E80F72AAQ34658477-012C886C-981C-48B9-8AC6-26BDA2E875ADQ35041422-64142945-7B72-4CEF-ACF3-EDAEF8886D08Q35117586-7B9E1D1C-ED48-4519-8AC2-C59851077070Q35371001-2C178CFB-9BBA-4167-AEF4-AFBEE15E7073Q35545362-084A26C8-8EAB-4A0A-999F-F0C9E9676D49Q35545370-C4F1AE6A-F02A-48C2-BF7D-349F7AE2FBC3Q35553783-4D60F9EE-9914-4D81-8050-BF7ED0B73500Q35987917-65101C72-69D4-4CEA-A9B4-E9071F3712A8Q36014089-DC26493C-4CC0-4F86-9E17-8969D5BD074AQ36391033-F26FC032-D4BE-46A8-B8EE-BE6A7810647FQ36484631-32418117-022C-4882-95C7-5FCD53995358Q36705351-E4C62028-F9F3-431B-8100-8A38FB2BFE9DQ36758710-7C7757C1-9E54-4D52-BB58-24B540AC3834Q36944623-792C31B3-05EF-45B6-9BBF-EB6FB1B54F50Q37338441-8CF2429A-392E-4AB6-8F06-3BCFC2733161Q37357935-0F898081-9719-45F9-90BF-58EB2F754BFFQ37672852-AB403A05-3198-4F7D-903F-4276DC357699Q37939132-B2FC66CC-1EFA-4399-AD74-DD3390A3F6FBQ38166623-EA07FC52-A2DE-4731-9162-B09B85238AEEQ38354744-EE358496-5251-488E-BA75-4042EF522A8BQ39193265-FDE53EBF-B056-455D-9680-41F65FF7FEA2Q39263982-0E96A389-E0C5-4D19-94BD-5783180410A1Q41863446-3169BC8F-1AF8-449C-84FA-7286FBC5B92CQ41881332-FD3FA075-A826-4D13-AD45-AA0959AF92C4Q41923460-A12B157E-A8D4-4F9C-946C-36CD7D2D8A94
P2860
Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Beta 1- and beta 2-adrenocepto ...... ions in chronic heart failure.
@ast
Beta 1- and beta 2-adrenocepto ...... ions in chronic heart failure.
@en
type
label
Beta 1- and beta 2-adrenocepto ...... ions in chronic heart failure.
@ast
Beta 1- and beta 2-adrenocepto ...... ions in chronic heart failure.
@en
prefLabel
Beta 1- and beta 2-adrenocepto ...... ions in chronic heart failure.
@ast
Beta 1- and beta 2-adrenocepto ...... ions in chronic heart failure.
@en
P1476
Beta 1- and beta 2-adrenocepto ...... tions in chronic heart failure
@en
P2093
P304
P577
1991-06-01T00:00:00Z